Pharmaceutical

Debiopharm, SunRock sign agreement for cancer ADCs

Debiopharm and SunRock Biopharma have signed an agreement to advance the development of specifically targeted ADCs for hard-to-treat cancers.

Sep 23, 2023 - 20:00
Debiopharm, SunRock sign agreement for cancer ADCs
Debiopharm and SunRock Biopharma have signed an agreement to advance the development of specifically targeted ADCs for hard-to-treat cancers.
Read the original article

Tags:

Previous Article

Glenmark Pharma to divest 75% stake in life sciences unit for $680m

Next Article

Chromosome-scale genome sequence of Suaeda glauca sheds light on salt stress tol...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Opinion: Current large language models will not fix health care. Here’s what could

Opinion: Current large language models will not fix hea...

Aug 25, 2023

Leading innovators in ssRNA virus peptides for the pharmaceutical industry

Leading innovators in ssRNA virus peptides for the phar...

May 8, 2023

FDA advisory panel recommends a streamlined flu vaccine for next fall

FDA advisory panel recommends a streamlined flu vaccine...

Mar 6, 2024